Trevi Therapeutics (TRVI) Stock Forecast: StockMap's 2-Week Call

TRVI stock forecast: StockMap's model leans Underperform on Trevi Therapeutics for the two weeks after the Nov 19 close, toward TRVI trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 1 of 3 two-week windows on TRVI since Oct 2; by chance, a call on the same dates was right 40% of the time.

Trevi Therapeutics last closed at $13.72, +1.55% on the session.

Against the IVW growth benchmark the position is +3.88% over the forecast window.

Trevi Therapeutics' market cap is $1.96B as of November 19, 2026.

Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -30 (too close to call).

Where TRVI sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 5 bullish and 10 bearish.

Agreement across those insights is 67%.

21 daily calls for TRVI so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Trevi Therapeutics in the 26th percentile on return on equity, where 100 is best.

Trevi Therapeutics is classified under Health Care / Pharmaceuticals.

StockMap tracks Trevi Therapeutics as the 43rd largest of the 153 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 80 Moderate Underperform, 44 Neutral and 29 Strong Underperform.

On that composite Trevi Therapeutics ranks 68th of 153 in the group, against a group median of -0.36.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 19, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

Trevi Therapeutics (TRVI) — StockMap 2-week forecast & tracked accuracy